Thursday, September 12, 2013
Baylor College of Medicine
researchers have uncovered a pathway in allergic asthma that opens up the
potential for developing therapeutics that target the causes of the disease
rather than just its symptoms.1 The team now has to show that the
pathway, which involves degradation of the blood clotting protein fibrinogen
by fungal allergens to cleavage products that activate toll-like
receptor 4, also applies to other allergens.
L. SciBX 6(35);
doi:10.1038/scibx.2013.947 Published online Sept. 12, 2013
1. Millien, V.O. et al.
Science; published online Aug. 16, 2013; doi:10.1126/science.1240342 Contact:
Farrah Kheradmand, Baylor College of Medicine, Houston, Texas e-mail: email@example.com
Contact: David B. Corry, same affiliation as above e-mail: firstname.lastname@example.org
2. Kheradmand, F. et al.
J. Immunol. 169, 5904-5911 (2002)
3. Hammad, H. et al.
Nat. Med. 15, 410-416 (2009)
4. Hodgkinson, C.P. et
al. Thromb. Haemost. 100, 301-307 (2008)
AND INSTITUTIONS MENTIONED
Baylor College of Medicine, Houston, Texas
Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland
InDex Pharmaceuticals AB, Stockholm, Sweden
Mayo Clinic, Rochester, Minn.
Michael E. DeBakey VA Medical Center, Houston, Texas
The University of Texas Health Science Center at Houston, Houston, Texas